The final raltegravir PBPK model applies metabolism by UGT1A1,  UGT1A9 and glomerular filtration and adequately describes the pharmacokinetics of raltegravir in adults receiving SD, MD of Raltegravir ranging from 10mg to 1600mg, including four different oral formulations. 

This model could be applied for the investigation of DDI, and translation to special populations such as pediatrics.
